Skip to main content
SpringerLink
Log in

Platinum anticancer drugs

  • Chapter
Metal Compounds in Cancer Therapy

Abstract

Currently, the anticancer drugs based on platinum, cisplatin (CDDP; cis-diamminedichloroplatinum(II)) and its analogue carboplatin (CBDCA; cis-diammine(l,l-cyclobutane dicarboxylato)platinum(II)) are by far the most important metal compounds used in cancer therapy (see Figure 2.1 for structures). The discovery of the antitumour properties of cisplatin in the mid-1960s by Barnett Rosenberg while performing experiments investigating the effects of electric fields on bacteria is an example of modern-day serendipity (review: Rosenberg, 1985). Interestingly, the chemical identity of cisplatin was first established over 100 years previously in 1845, whereupon it was known for many decades as Peyrone’s chloride.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br. Med. J., 303, 884–893.

    Article  Google Scholar 

  • Andrews, P. A. and Howell, S. B. (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35–43.

    PubMed  CAS  Google Scholar 

  • Andrews, P. A. and Jones, J. A. (1991) Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Cancer Commun., 3, 1–10.

    CAS  Google Scholar 

  • Beck, D. J., Popoff, S., Sancar, A. and Rupp, W. D. (1985) Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloro-platinum(II). Nucleic Acids Res., 13, 7395–7412.

    Article  PubMed  CAS  Google Scholar 

  • Bedford, P., Fichtinger-Schepman, M. J., Shellard, S. A. et al. (1988) Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res., 48, 3019–3024.

    PubMed  CAS  Google Scholar 

  • Bellon, S.F., Coleman, J. H. and Lippard, S. J. (1991) DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis- diamminedichloroplatinum(II). Biochemistry, 30, 8026–8035.

    Article  PubMed  CAS  Google Scholar 

  • Bissett, D., McLaughlin, K., Kelland, L. R. and Brown, R. (1993). Cisplatin-DNA damage recognition proteins in human tumour extracts. Br. ]. Cancer, 67, 742–748.

    Article  CAS  Google Scholar 

  • Bruhn, S. L., Pil, P. M., Essigmann, J. M. et al. (1992) Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl Acad. Sci. USA, 89, 2307–2311.

    Article  PubMed  CAS  Google Scholar 

  • Burchenal, J. H., Kalaher, K., Dew, K. and Lokys, L. (1979) Rationale for development of platinum analogs. Cancer Treat. Rep., 63, 1493–1498.

    PubMed  CAS  Google Scholar 

  • Calvert, A. H., Newell, D. R. and Gore, M. E. (1992) Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin? Semin. Oncol., 19, 155–163.

    PubMed  CAS  Google Scholar 

  • Calvert, A. H., Newell, D. R., Gumbrell, L. A. et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 1748–1756.

    PubMed  CAS  Google Scholar 

  • Canetta, R., Rozencweig, M., Wittes, R. E. and Schacter, L. P. (1990) Platinum coordination complexes in cancer chemotherapy: an historical perspective, in Cancer Chemotherapy; Challenges for the Future, Vol. 5, Excerpta Medica Ltd, Tokyo, pp. 318–323.

    Google Scholar 

  • Chao, C. C-K., Huang, S-L., Lee, L-Y. and Lin-Chao, S. (1991) Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to ds-diamminedichloroplatinum (II). Biochem. J., 277, 875–878.

    PubMed  CAS  Google Scholar 

  • Christian, M. C., Kohn, E., Sarosy, G. et al. (1992) Phase I and pharmacologie study of ormaplatin (OP)/tetraplatin. Proc. Am. Soc. Clin. Oncol., 11, 117 (Abstract 291).

    Google Scholar 

  • Chu, G. and Chang, E. (1988) Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science, 242, 564–567.

    Article  PubMed  CAS  Google Scholar 

  • Chu, G. and Chang, E. (1990) Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl Acad. Sci. USA, 87, 3324–3327.

    Article  PubMed  CAS  Google Scholar 

  • Clugston, C. K., McLaughlin, K., Kenny, M. K. and Brown, R. (1992) Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug ds-diamminedichloroplatinum(II). Cancer Res., 52, 6375–6379.

    PubMed  CAS  Google Scholar 

  • Comess, K. M. and Lippard, S. J. (1993) Molecular aspects of platinum-DNA interactions, in Anticancer Drug-DNA interactions, Vol. 1 (eds S. Neidle and M. Waring), MacMillan, London, pp. 134–368.

    Google Scholar 

  • Connors, T. A., Cleare, M. J. and Harrap, K. R. (1979) Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep., 63, 1499–1502.

    PubMed  CAS  Google Scholar 

  • Coverley, D., Kenny, M. K., Lane, D. P. and Wood, R. D. (1992) A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res., 20, 3873–3880.

    Article  PubMed  CAS  Google Scholar 

  • Donahue, B. A., Augot, M., Bellon, S. F. et al. (1990) Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry, 29, 5872–5880.

    Article  PubMed  CAS  Google Scholar 

  • Eastman, A. (1986) Reevaluation of interaction of ds-dichloro (ethylene-diamine) platinum(II) with DNA. Biochemistry, 25, 3912–3915.

    Article  PubMed  CAS  Google Scholar 

  • Eastman, A. and Barry, M. A. (1987) Interaction of frans-diamminedichloro-platinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry, 26, 3303–3307.

    Article  PubMed  CAS  Google Scholar 

  • Egorin, M. J., Van Echo, D. A., Tipping, S. J. et al. (1984) Pharmacokinetics and dose reduction of ds-diammine (1,1-cyclobutane dicarboxylato) platinum(II) in patients with impaired renal function. Cancer Res., 44, 5432–5438.

    PubMed  CAS  Google Scholar 

  • Eisenhauer, E., Swerton, K., Sturgeon, J. et al. (1990) Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature, in Carboplatin; Current Perspectives and Future Directions (eds P. Bunn, R. Canetta, R. Ozols and M. Rozencweig), W. B. Saunders Company, Philadelphia, pp. 133–140.

    Google Scholar 

  • Fichtinger-Schepman, A. M. J., van der Veer, J. L., den Hartog, J. H. J. et al. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry, 24, 707–713.

    Article  PubMed  CAS  Google Scholar 

  • Goddard, P. M., Valenti, M. R. and Harrap, K. R. (1991) The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann. Oncol., 2, 535–540.

    PubMed  CAS  Google Scholar 

  • Gore, M., Fryatt, I., Wiltshaw, E. et al. (1989) Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer, 60, 767–769.

    Article  PubMed  CAS  Google Scholar 

  • Hansson, J. and Wood, R. D. (1989) Repair synthesis by human cell extracts in DNA damaged by cis-and trans-diamminedichloroplatinum(II). Nucleic Acids Res., 17, 8073–8091.

    Article  PubMed  CAS  Google Scholar 

  • Harland, S. J., Newell, D. R., Siddik, Z. H. et al. (1984) Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res., 44, 1693–1697.

    PubMed  CAS  Google Scholar 

  • Harrap, K. R. (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev., 12 (Suppl. A), 21–33.

    Article  PubMed  CAS  Google Scholar 

  • Harrap, K. R., Murrer, B. A., Giandomenico, C. et al. (1991) Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (ed. S. B. Howell), Plenum Press, New York, 391–399.

    Google Scholar 

  • Horwich, A., Mason, M. and Dearnaley, D. P. (1992) Use of carboplatin in germ cell tumors of the testa’s. Semin. Oncol., 19 (Suppl. 2), 72–77.

    PubMed  CAS  Google Scholar 

  • Howell, S. B., Isonishi, S., Christen, R. C. et al. (1991) Signal transduction pathway regulation of DDP sensitivity, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy(ed. S. B. Howell), Plenum Press, New York, 173–179.

    Google Scholar 

  • Hughes, E. N., Engelsberg, B. N. and Billings, P. C. (1992) Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J. Biol Chem., 267, 13520–13527.

    PubMed  CAS  Google Scholar 

  • Isonishi, S., Horn, D. K., Thiebaut, F. B. et al. (1991) Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903–5909.

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Mistry, P., Abel, G. et al. (1992a) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res., 52, 1710–1716.

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Jones, M., Abel, G. and Harrap, K. R. (1992b) Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol, 30, 43–50.

    Article  PubMed  CAS  Google Scholar 

  • Kelland, L. R., Murrer, B. A., Abel, G. et al. (1992c) Ammine/amine platinum.(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52, 822–828.

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Mistry, P., Abel, G. et al. (1992d) Mechanism-related circumvention of cis-diamminedichloro platinum (II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res., 52, 3857–3864.

    PubMed  CAS  Google Scholar 

  • Kelland, L. R., Jones, M., Goddard, P. M. et al. (1992e) Preclinical antitumor activity of Bis-acetato-ammine dichloro (cyclohexylamine) platinum (IV) (JM216): an orally active platinum drug. Proc. Am. Assoc. Cancer Res., 33, A3342.

    Google Scholar 

  • Knox, R. J., Friedlos, F., Lydall, D. A. and Roberts, J. J. (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis diam-minedichloro platinum(II) and cis-diammine(l,l-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972–1979.

    PubMed  CAS  Google Scholar 

  • Loehrer, P. J. and Einhorn, L. H. (1984) Cisplatin, diagnosis and treatment. Ann. Intern. Med., 100, 704–713.

    PubMed  CAS  Google Scholar 

  • Mangioni, C., Bolis, G., Pecorelli, S. et al. (1989) Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst., 81, 1464–1468.

    Article  PubMed  CAS  Google Scholar 

  • McGuire III, W. P., Arseneau, J., Blessing, J. A. et al. (1989) A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol., 7, 1462–1468.

    Google Scholar 

  • McKeage, M. J. and Kelland, L. R. (1993) New platinum drugs in Anticancer Drug-DNA Interactions, Vol. 1 (eds S. Neidle and M. Waring) MacMillan, London, pp. 169–212.

    Google Scholar 

  • McKeage, K. J., Morgan, S. E., Boxall, F. E. et al. (1992) Acute toxicology of orally administered bis-acetato-ammine dichloro (cyclohexylamine) platinum(IV) (JM216) in rodents. Proc. Am. Assoc. Cancer Res., 33, A3197.

    Google Scholar 

  • Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E. L. et al. (1991) Long-term survival in ovarian cancer. Eur. ]. Cancer, 11, 1367–1372.

    Article  Google Scholar 

  • Ozols, R. F. (1991) Ovarian cancer: new clinical approaches. Cancer Treat. Rev., 18, (Suppl. A), 77–83.

    Article  PubMed  Google Scholar 

  • Ozols, R. F. (1992) New developments with carboplatin in the treatment of ovarian cancer. Semin. Oncol., 19 (Suppl. 2), 85–89.

    PubMed  CAS  Google Scholar 

  • Page, J. D., Husain, I., Sancar, A. and Chaney, S. G. (1990) Effect of diaminocyclohexane carrier ligand on platinum adduct formation, repair and lethality. Biochemistry, 29, 1016–1024.

    Article  PubMed  CAS  Google Scholar 

  • Parker, R. J., Gill, I., Tarone, R. et al. (1991) Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis, 12, 1253–1258.

    Article  PubMed  CAS  Google Scholar 

  • Pera, M. F., Friedlos, F., Mills, J. and Roberts, J. J. (1987) Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloro platinum (II) on DNA. Cancer Res., 47, 6810–6813.

    PubMed  CAS  Google Scholar 

  • Pil, P. M. and Lippard, S. J. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science, 256, 234–237.

    Article  PubMed  CAS  Google Scholar 

  • Reed, E., Ozols, R. F., Tarone, R. et al. (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl Acad. Sci. USA, 84, 5024–5028.

    Article  PubMed  CAS  Google Scholar 

  • Roberts, J. J., Knox, R. J., Friedlos, F. and Lydall, D. A. (1986) DNA as the target for the cytotoxic and anti-tumour action of platinum coordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin, in Biochemical Mechanisms of Platinum Antitumour Drugs (eds D. C. H. McBrien and T. F. Slater), IRL Press, Oxford, pp. 29–64.

    Google Scholar 

  • Rosenberg, B. (1979) Anticancer activity of cis-diamminedichloro platinum (II) and some relevant chemistry. Cancer Treat. Rep., 63, 1433–1438.

    PubMed  CAS  Google Scholar 

  • Rosenberg, B. (1985) Fundamental studies with cisplatin. Cancer (Phil), 55, 2303–23016.

    Article  CAS  Google Scholar 

  • Smith, I. E. and Talbot, D. C. (1992) Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br. J. Cancer, 65, 787–793.

    Article  PubMed  CAS  Google Scholar 

  • Szymkowski, D. E., Yarema, K., Essigmann, J. M. et al. (1992) An intrastrand d(GpG) platinum crosslink in duplex M13DNA is refractory to repair by human cell extracts. Proc. Natl Acad. Sci. USA, 89, 10772–107726.

    Article  PubMed  CAS  Google Scholar 

  • Trask, C., Silverstone, A., Ash, C. M. et al. (1991) A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J. Clin. Oncol., 9, 1131–1137.

    PubMed  CAS  Google Scholar 

  • Walker, M.C., Parris, C. N. and Masters, J. R. W. (1987) Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J. Natl Cancer Inst., 79, 213–216.

    PubMed  CAS  Google Scholar 

  • Wiltshaw, E. and Carr, B. (1974) Cis-platinumdiamminedichloride, in Platinum Coordination Complexes in Cancer Chemotherapy, (eds T. A. Connors and J. J. Roberts), Springer-Verlag, Heidelberg, pp. 178–182.

    Chapter  Google Scholar 

Download references

Authors
  1. Lloyd R. Kelland
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johnson Matthey Technology Centre, Reading, UK

    Simon P. Fricker

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kelland, L.R. (1994). Platinum anticancer drugs. In: Fricker, S.P. (eds) Metal Compounds in Cancer Therapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1252-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1252-9_2

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4545-2

  • Online ISBN: 978-94-011-1252-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation